1.Current usage: What are the current diagnostic methods you use to assess response to solid tumor therapy when using ImmunoOncology (IO)?

Please check all that apply
2.Time to test: At what time point(s) do you routinely do imaging or other tests to assess response?
3.Utility of test: If the patient is on IO and the initial scan shows some enlargement, what is your usual/preferred response?
Please check all that apply
4.Test result reporting: For currently available liquid biopsy tests - what is the typical lag time - including preapproval, scheduling, performing, reading and reporting – between when you order a liquid biopsy, for any purpose, and when you receive the final report?
5.For the all questions below assume there was a test that was both inexpensive and reliable, that could determine biochemically, using cfDNA methylation, if a therapy for advanced cancer was working early in the course of treatment. Assume a University of Colorado lab supplied the result the day of receipt.

Please check all that apply.

Therapy Evaluation: Would you use this test?
6.Your location vs. Mail in Lab Testing: : If you could do this test in your office lab instead of waiting for overnight lab results, would you use it more?
7.Importance of Therapy Outcome Information: How important is it for you and your patients’/families to know if a new treatment is reducing or controlling cancer?

Please check all that apply
8.Testing Frequency with Plasma vs. Urine Samples:How often would you use the test described above, and would the sample type (plasma or urine) matter?

Please check all that apply
9.What price would make such a test too expensive to use monthly whether, reimbursed (by CMS and others) or self-pay ?

Please check one for reimbursed and one for self-pay.
10.Hospice Care : Therapy to reduce the growth rate of cancer in a hospice setting may reduce symptoms, however it may also cause side effects : in what percent of patients would you test to see if a therapy was having an effect on cancer growth?